Genetics and treatment history influence clonal hematopoiesis risk after PARP inhibitor therapy

IF 25.5 1区生物学 Q1 GENETICS & HEREDITY

Nature genetics Pub Date : 2026-09-29 DOI:10.1038/s41588-026-02749-x

引用次数: 0

Abstract

PARP inhibitors and platinum chemotherapy both promote expansion of blood stem cell clones carrying leukemia-associated mutations, but inherited defects in homologous recombination limit this process. These findings reveal that therapy-related leukemia risk may depend on an interaction between treatment history and inherited genetics.

查看原文本刊更多论文

遗传和治疗史影响PARP抑制剂治疗后克隆造血风险。

PARP抑制剂和铂类化疗都能促进携带白血病相关突变的造血干细胞克隆的扩增，但同源重组中的遗传缺陷限制了这一过程。这些发现表明，治疗相关的白血病风险可能取决于治疗史和遗传基因之间的相互作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature genetics 生物-遗传学

CiteScore

43.00

自引率

2.60%

发文量

241

审稿时长

3 months

期刊介绍： Nature Genetics publishes the very highest quality research in genetics. It encompasses genetic and functional genomic studies on human and plant traits and on other model organisms. Current emphasis is on the genetic basis for common and complex diseases and on the functional mechanism, architecture and evolution of gene networks, studied by experimental perturbation. Integrative genetic topics comprise, but are not limited to: -Genes in the pathology of human disease -Molecular analysis of simple and complex genetic traits -Cancer genetics -Agricultural genomics -Developmental genetics -Regulatory variation in gene expression -Strategies and technologies for extracting function from genomic data -Pharmacological genomics -Genome evolution